{"title":"HER2/neu 低表达乳腺癌的特征","authors":"","doi":"10.32471/clinicaloncology.2663-466x.50-2.30634","DOIUrl":null,"url":null,"abstract":"early disease stages. It was determined that the frequency of BC recurrences was higher in patients with greater HER2 expression, but it was not statistically significant, p >0.05. Conclusions. The obtained results propose general concepts of HER2-low BC and require further study","PeriodicalId":487505,"journal":{"name":"Клиническая онкология","volume":"64 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Особливості перебігу раку грудної залози з низьким рівнем експресії HER2/neu\",\"authors\":\"\",\"doi\":\"10.32471/clinicaloncology.2663-466x.50-2.30634\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"early disease stages. It was determined that the frequency of BC recurrences was higher in patients with greater HER2 expression, but it was not statistically significant, p >0.05. Conclusions. The obtained results propose general concepts of HER2-low BC and require further study\",\"PeriodicalId\":487505,\"journal\":{\"name\":\"Клиническая онкология\",\"volume\":\"64 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Клиническая онкология\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.32471/clinicaloncology.2663-466x.50-2.30634\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Клиническая онкология","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.32471/clinicaloncology.2663-466x.50-2.30634","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Особливості перебігу раку грудної залози з низьким рівнем експресії HER2/neu
early disease stages. It was determined that the frequency of BC recurrences was higher in patients with greater HER2 expression, but it was not statistically significant, p >0.05. Conclusions. The obtained results propose general concepts of HER2-low BC and require further study
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
